A year-end update on WM, a distinct entity of lymphoplasmacytic lymphoma presenting with monoclonal pleomorphic immunoglobulin M (IgM) proteins, was recently published in the American Journal of Hematology.
Researchers sought to identify possible prognostic markers in extranodal natural killer T-cell lymphoma through an analysis of gene expression profiling data.
Researchers sought to determine whether first-line chemotherapy followed by high-dose therapy and auto-SCT would be the preferred treatment for patients under 60 with T-NHL.
In patients who had received at least 2 prior therapy lines, the overall response rates were 49.9% in SCHOLAR-5 vs 94.2% in ZUMA-5.
The overall response rate was 44.7% after a median follow-up of 15 months.
The median overall survival was not reached at 3 years.
The 7-year survival results were superior with MATRIX.
Relapsed/refractory disease and older age were also associated with prolonged hospital stay and death.
Researchers sought to identify factors that may contribute to failure with CAR T cell therapy in patients with LBCL.
Six patients experienced a grade 5 treatment-related adverse event.
This analysis compared infection-related hospitalization and death among patients 70 years of age and older with DLBCL treated with full-dose vs attenuated-dose R-CHOP.
Zanubrutinib is marketed under the trade name Brukinsa and is currently indicated for the treatment of mantle cell lymphoma.
Researchers sought to determine whether pirtobrutinib would be effective and tolerable in heavily pretreated patients with mantle cell lymphoma.
Researchers sought to determine whether combining nivolumab with brentuximab vedotin would be safe and effective in treating patients with mediastinal gray zone lymphoma.
Zynlonta (loncastuximab tesirine-lpyl) is a CD19-directed antibody and alkylating agent conjugate.
Researchers sought to investigate the associations between PTSS and the experiences of pediatric survivors of Hodgkin lymphoma treated in the AHOD0031 study.
Baseline alcohol consumption was associated with a higher QOL score compared with never use of alcohol.
Researchers sought to update and assess the interim efficacy, futility, and safety in the phase 3 SPARKLE trial.
Investigators report on findings from the MARIETTA study, which evaluated an intensive, CNS-directed chemoimmunotherapy followed by autoHSCT in patients with secondary CNS lymphoma.
Combination therapy of anti-PD-1 camrelizumab plus decitabine led to longer response in patients with relapsed/refractory Hodgkin lymphoma.
Researchers sought to determine the safety and efficacy of brentuximab vedotin in pediatric patients with classical Hodgkin lymphoma.
Researchers sought to determine whether AB-205 would be a safe and effective therapy added to HDT-AHCT in adult patients with lymphoma.
An international, retrospective study was conducted to assess outcomes following alloHCT after PD-1 blockade in Hodgkin lymphoma.
Researchers sought to determine whether hypomagnesemia increases the risk of failure for autologous hematopoietic stem cell transplantation in patients with DLBCL.
A team of investigators sought to determine if treatment efficacy can be maintained without radiotherapy among patients with newly diagnosed, early-stage, unfavorable Hodgkin lymphoma.
Researchers sought to determine whether R-MegaCHOEP would improve outcomes compared to R-CHOEP-14 in patients with newly diagnosed, aggressive B-cell lymphoma.
The approval was based on data from the single-arm, open-label phase 2 ZUMA-5 study.
A team of investigators sought to assess the safety and efficacy of lenalidomide plus R-CHOP in patients with previously untreated activated B-cell-like subtype of diffuse large B-cell lymphoma.
Investigators assessed outcomes following a radiotherapy dose of 4 Gy in 2 fractions vs 24 Gy in 12 fractions in patients with follicular lymphoma or marginal zone lymphoma.
Investigators will study the pharmacokinetic and pharmacodynamic profile of TG-1701, an irreversible Bruton tyrosine kinase (BTK) inhibitor, in the phase 1 setting.
The ZUMA-5 trial studied whether CAR T cell therapy with axi-cel had any clinical benefits in patients with indolent NHL.
Investigators of a phase 3 trial will compare epcoritamab with investigator’s choice of chemotherapy in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
The FDA has accepted a supplemental new drug application (sNDA) for brukinsa for the treatment of adults with Waldenström Macroglobulinemia (WM).
The approval was based on data from the open-label, multi-cohort phase 2 UNITY-NHL Trial.
As follicular lymphoma (FL) survival rates have improved, concern that patients are at increased risk for the development of a secondary primary malignancy (SPM) has arisen.
Chimeric antigen receptor (CAR)-T cells can kill off-target tumor cells in the vicinity of the target cells, a phenomenon known as bystander killing. Modulating the expression of the protein mediating this process—Fas—could be a strategy to improve CAR-T efficacy.
The approval was based on data from an open-label phase 1/2 trial in patients aged 1 to 21 years that included 26 patients with relapsed or refractory, systemic ALK-positive ALCL after at least 1 systemic treatment.
Experts discuss clinical, pathologic, and genomic features of Burkitt lymphoma in adults, as well as standard and emerging treatment options for this patient population.
Nearly half of all relapses occurred within the first month of CAR-T infusion.
Peripheral T-cell lymphoma is characterized by extensive epigenetic dysregulation.
Loncastuximab tesirine is an antibody drug conjugate composed of a humanized monoclonal antibody directed against human CD19 and conjugated through a linker to a pyrrolobenzodiazepine dimer cytotoxin.
Investigators summarize current literature surrounding the treatment of NLPHL and discuss treatment considerations for 2 clinical cases.
Researchers report on results with CAR-T therapy in real-world populations of patients with ALL or NHL.
A retrospective analysis highlights the reasons for discontinuation of ibrutinib among patients with mantle cell lymphoma.
Adults treated for Hodgkin lymphoma have an increased risk of death from heart disease, interstitial lung disease, infections, and adverse effects of therapy.
Depending on the type and stage of lymphoma, physicians may choose to avoid having their patients undergo radiation therapy for fear of potential toxic effects in organs.
Small studies, the absence of subtypes, and a historical lack of genetic information has stopped past studies from triggering meaningful public health change, a review asserts.
Exposure to doxorubicin during treatment for DLBCL was linked to a higher risk for cardiovascular diseases, highlighting the need for early cardiac surveillance.
Among patients with early-stage, favorable Hodgkin lymphoma, treatment regimens with conventional chemotherapy may be effective in a subset of patients.
Tazemetostat yielded clinically meaningful, durable responses and was well tolerated in patients with relapsed or refractory follicular lymphoma.
Responses were also observed in patients previously treated with HDAC or mTOR inhibitors.